Segment Reporting

12 Months Ended

Jun. 30, 2013

Segment Reporting [Abstract]

Segment Reporting

Segment Reporting

Management reviews financial information, allocates resources and manages the business as two segments, Sonomed-Escalon and Escalon Medical Corp. The Sonomed-Escalon segment consists of Sonomed, Escalon Digital Imaging and Trek, all of which are engaged in the development and sale of Ophthalmic medical devices. The Escalon Medical Corp. segment presents the administrative corporate operations of the consolidated group.

The table below sets forth the loss from continuing operations for the years ended June 30, 2013 and 2012.

	Sonomed Escalon						Corporate						Total
	2013			2012			2013			2012			2013			2012
Revenues, net:
Product revenue	$	11,497		$	11,462		$	—		$	—		$	11,497		$	11,462
Total revenue, net	11,497			11,462			—			—			11,497			11,462
Costs and expenses:
Cost of goods sold	5,905			5,760			—			—			5,905			5,760
Marketing, general & admin	5,300			5,540			419			476			5,718			6,016
Research & development	1,105			1,005			—			—			1,105			1,005
Total costs and expenses	12,310			12,304			419			476			12,729			12,781
(Loss) from operations	(813		)	(843		)	(419		)	(476		)	(1,231		)	(1,319		)
Other (expense) and income:
Other income (expense)	—			—			78			7			78			7
Interest income	—			—			—			—			—			—
Interest expense	—			—			(79		)	(339		)	(79		)	(339		)
Total other (expense) and income	—			—			(1		)	(332		)	(1		)	(332		)
(Loss) before taxes	(813		)	(843		)	(420		)	(808		)	(1,233		)	(1,651		)
Income taxes benefit from continuing operations	—			—			—			—			—			—
Net (loss) income from continuing operations	$	(813	)	$	(843	)	$	(420	)	$	(808	)	$	(1,233	)	$	(1,650	)

The Company operates in the healthcare market, specializing in the development, manufacture and marketing of ophthalmic medical devices and pharmaceuticals. The business segments reported above are the segments for which separate financial information is available and for which operating results are evaluated regularly by executive management in deciding how to allocate resources and assessing performance. The accounting policies of the business segments are the same as those described in the summary of significant accounting policies. For the purposes of this illustration, corporate expenses, which consist primarily of executive management and administrative support functions, are allocated across the business segments based upon a methodology that has been established by the Company, which includes a number of factors and estimates and that has been consistently applied across the business segments. These expenses are otherwise included in the corporate segment.

During the fiscal years ended June 30, 2013 and 2012, Sonomed-Escalon derived its revenue from the sale of A-Scans, B-Scans and pachymeters. These products are used for diagnostic or biometric applications in ophthalmology. Revenue from the sale of ISPAN gas products and various disposable ophthalmic surgical products are from CFA digital imaging systems and related products.

No customer represented more than 10% of consolidated revenue from continuing operations for the years ended June 30, 2013 and 2012. Foreign sales in 2013 decreased $1,003,560 or 17.6% to $4,714,209.

	2013			2012
Sonomed-Escalon	$	4,714,209		$	5,717,769
Total	$	4,714,209		$	5,717,769
Total Net Revenue	$	11,496,834		$	11,461,531
	41.0		%	49.9		%